Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B.
Journal: Journal of cardiac failure
Published: October 24, 2025
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. Reply.
Journal: The New England journal of medicine
Published: May 07, 2025
Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B.
Journal: Journal of the American College of Cardiology
Published: February 20, 2025
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B.
Journal: Journal of the American College of Cardiology
Published: February 08, 2025
Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy.
Journal: Journal of the American College of Cardiology
Published: January 29, 2025
Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial.
Journal: Journal of the American College of Cardiology
Published: November 02, 2024
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.
Journal: The New England journal of medicine
Published: August 30, 2024
A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen.
Journal: CPT: pharmacometrics & systems pharmacology
Published: July 25, 2022
An age-dependent mathematical model of neurofilament trafficking in healthy conditions.
Journal: CPT: pharmacometrics & systems pharmacology
Published: October 15, 2021
Last Updated: 09/26/2026